The company betting that the most expensive corner of American medicine - cancer, cardiology, and back surgery - can be run better when the people paying for care and the doctors delivering it are finally pulling in the same direction.
Almost everyone in America has a story about a phone call - the one where an insurance company said no, or not yet, or not that drug. It is the most reliably hated moment in the health system, and it usually happens right when the diagnosis is at its scariest: cancer, a heart condition, a spine that has stopped cooperating. Evolent, a company most people have never heard of, has built its entire business around that moment - and around a stubborn idea that it can be run better.
Headquartered in Arlington, Virginia, Evolent is not an insurer and not quite a hospital. It sits in between. It contracts with health plans to manage the cost and quality of the most expensive specialties in medicine - oncology, cardiology, and musculoskeletal care - and it does so with an unusual toolkit: its own doctors and nurses, a library of evidence-based clinical pathways, and a technology platform called Identifi. The pitch to insurers is blunt. Hand us your hardest, priciest cases, and we will not just review them. We will take financial risk on how they turn out.
That last part is what makes the company worth understanding. Most of the middlemen in American healthcare get paid whether or not care improves. Evolent's model is designed so that when it steers a patient toward the right treatment - the one supported by clinical evidence, which is often less invasive and less expensive - everyone is supposed to win: the plan, the provider, and the person on the table.
Evolent was founded in 2011 by Frank Williams, Seth Blackley, and Tom Peterson. It was not a garage startup. Williams had already built and run The Advisory Board Company, and Evolent began life as a joint venture between The Advisory Board and UPMC, the Pittsburgh-based health system and insurer. The founders were betting on a shift that everyone in healthcare talked about but few knew how to execute: the move from fee-for-service, where the system gets paid for doing more, to value-based care, where it gets paid for doing better.
That shift has taken longer than almost anyone predicted, which is part of why Evolent's patience matters. The company went public on the New York Stock Exchange in 2015 under the ticker EVH. Williams led it through its first decade; in 2020, co-founder Seth Blackley took over as chief executive, a role he still holds.
The reason Evolent staffs more than 1,300 clinicians - roughly 400 physicians and 750 nurses inside what is often described as a "health tech" company - is that specialty care management is, at bottom, a trust problem before it is a software problem. When an oncologist proposes a treatment plan, the party on the other end of the decision needs clinical credibility, not just a call-center script.
Evolent's approach is to put an evidence-based pathway and, often, a peer specialist behind each decision. The company reports that its programs typically raise adherence to clinical pathways by more than 30 percent. In plain terms: more patients end up on the treatment the medical evidence actually supports, and fewer end up on the expensive detour. Prior authorization, the phrase everyone loves to hate, becomes less a wall and more a conversation between specialists.
Illustrative relative spend intensity across the categories Evolent manages. A small share of members drives a large share of specialty cost.
For years Evolent was, confusingly, a family of names. Oncology and cardiology lived under New Century Health. Musculoskeletal, radiology, physical medicine, and genetic testing sat inside NIA. Surgical management ran through IPG. End-of-life and advanced-illness support came from Vital Decisions. In 2023 the company folded all of it into a single identity - Evolent - and pointed the whole organization at value-based specialty care.
Underneath the specialties is Identifi, Evolent's technology platform. It integrates clinical data, analytics, and workflow so that the pathways, the provider engagement, and the plan's economics all run off the same set of facts. It is the connective tissue that lets a company of this size make consistent decisions across roughly 40 million members.
Evolent's customers are not patients directly - they are the organizations that carry the risk for those patients. National and regional health plans, Medicare Advantage and Medicaid plans, health systems, and physician organizations contract with Evolent to manage a specialty or a population. The patient rarely knows Evolent is in the room, which is exactly the point: the company operates as infrastructure, sitting quietly between an insurer and an oncologist.
There is a second reason the clinician count matters. Health plans are wary of vendors who have never sat across from a frightened patient or a proud surgeon. By putting practicing oncologists, cardiologists, and nurses on staff, Evolent can defend a decision on clinical grounds and, when the evidence genuinely supports the more aggressive path, say yes without flinching. Expertise, in this business, is not a marketing word. It is the thing being sold.
Evolent makes money two ways. In some contracts it charges technology-and-services fees for running a specialty program. In others - the more interesting ones - it takes on capitated or risk-based arrangements, meaning it is on the hook for a share of the total cost of care in a specialty and shares in the savings when that care is delivered more efficiently. The model is deliberately capital-light: Evolent does not own the hospitals or employ the treating physicians. It layers its clinicians, pathways, and platform on top of networks that already exist.
That structure has carried the company past $2 billion in annual revenue. And in 2025 Evolent made its priorities unmistakable. It agreed to sell its value-based primary care business, Evolent Care Partners - a large Medicare Shared Savings Program participant working with more than 1,000 physicians - to Privia Health for up to $113 million. The message was focus: specialty care is the bet.
From joint venture to focused specialty-care company.
Evolent is not alone in noticing that specialty care is where the dollars are. It competes with the giants - Optum, part of UnitedHealth Group, and Carelon, the health-services arm of Elevance Health - as well as with focused players like Cotiviti, Cohere Health, and Lumeris, and with the in-house utilization-management teams that payers run themselves. What differentiates Evolent is less any single product than its willingness to combine clinical staffing, pathways, and financial risk in one package. Plenty of vendors will sell an insurer a dashboard. Fewer will put their own money behind the outcome.
Zoom out, and Evolent occupies a specific seat in the long, grinding transition of American healthcare away from paying for volume. The economics are unforgiving: a small share of members drives a large share of cost, and most of that cost is concentrated in exactly the specialties Evolent manages. If value-based care is going to work anywhere, it has to work here first. That is both the opportunity and the difficulty - the model only pays off if the company is genuinely better at directing care, not just at negotiating.
The recent numbers suggest the market is buying it. Through 2025 and into 2026, Evolent has continued to report growth, profitability, and cash flow, and it has kept signing new specialty contracts across Medicare, Medicaid, and commercial populations. The divestiture of its primary care arm was not a retreat but a narrowing - proceeds went to paying down debt and sharpening the specialty focus. In an industry that rewards patience, a company founded in 2011 is only now hitting its stride.
For a company that operates almost entirely in the background, Evolent has a surprisingly clear thesis. The scary phone call is not going away. But who is on the other end of it, and what they are looking at when they make the decision, can change. Evolent's wager is that a specialist reading an evidence-based pathway beats a form letter - and that insurers will pay for the difference.